A bone met, short for bone metastasis, occurs when cancer cells spread from their original site to bone tissue. This secondary cancer forms most often from breast, lung, or prostate cancers. Unlike primary bone cancers, which start in the bones, metastases originate elsewhere.
Cancer cells enter the bloodstream or lymphatic system, travel to bones, and establish new tumors. They disrupt normal bone remodeling by secreting factors that activate osteoclasts (bone-destroying cells) and inhibit osteoblasts (bone-forming cells). This imbalance weakens bones and causes pain.
Bone mets commonly affect the spine, pelvis, ribs, and femur due to their high blood flow and marrow activity. For example, breast cancer metastasizes to bone in 65-75% of advanced cases, according to the American Cancer Society.
| Primary Cancer Site | Frequency | Common Met Sites |
|---|---|---|
| Breast | 70-80% | Spine, ribs, long bones |
| Prostate | 65-70% | Pelvis, spine, ribs |
| Lung | 30-40% | Spine, ribs, skull |
For instance, denosumab (a monoclonal antibody) reduces skeletal complications by 17% in solid tumors with bone mets, per the FDA.
Bone mets differ from primary bone cancers (like osteosarcoma) in origin, treatment, and prognosis. Primary cancers start in bone cells, while mets originate elsewhere. Primary bone cancers are rarer, affecting ~0.2% of the population annually (National Cancer Institute).
I once helped a patient understand this distinction when reviewing her imaging results. She had assumed her breast cancer was "just" spreading to bone, unaware of the unique challenges bone mets present.
Early detection of primary cancers reduces metastasis risk. Regular screenings and follow-ups help monitor high-risk patients. Bisphosphonates or denosumab may prevent or delay bone mets in certain cancers.